Analyst Allen Lutz of Bank of America Securities reiterated a Buy rating on Healthequity, retaining the price target of $125.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Allen Lutz has given his Buy rating due to a combination of factors that highlight HealthEquity’s strong market position and potential for growth. The company has shown a solid performance with a slight revenue increase and significant margin improvements, which are expected to continue as they leverage automation and AI to enhance service efficiency. Additionally, HealthEquity is strategically positioned to benefit from the growth of the Health Savings Account (HSA) market, particularly with the upcoming eligibility of approximately 7 million Bronze ACA accounts for HSA accounts.
Furthermore, HealthEquity’s ability to capitalize on mergers and acquisitions, along with its partnerships with integrated partners, provides a competitive edge. Despite some challenges, such as fraud costs impacting the profit and loss statement, these have spurred product and mobile app advancements. Overall, the company’s long-term margin expansion prospects and potential legislative benefits in the HSA market underpin the Buy rating and a price objective of $125.
In another report released today, Citizens JMP also maintained a Buy rating on the stock with a $122.00 price target.